NGL Fine-Chem Ltd. (IN:NGLFINE)
:NGLFINE
Want to see IN:NGLFINE full AI Analyst Report?
Top Page
NGL Fine-Chem Ltd.
(NGLFINE)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹3,047.00
▲(113.52% Upside)
Action:Upgraded
Date:05/23/26
The score is driven by strong technical momentum and trend strength, supported by improved growth and profitability. It is held back mainly by weak cash conversion and sustained negative free cash flow, alongside notable gross margin compression; valuation is moderate-to-high but cushioned by a strong dividend yield.
Positive Factors
Revenue Growth Momentum
Sustained re-acceleration of revenue (22.6% in 2026) indicates recovering end-market demand and better commercial traction. Over 2–6 months this supports higher capacity utilization, revenue visibility and the potential to convert scale into steadier operating profits if the trend persists.
Negative Factors
Gross Margin Compression
A material gross margin decline (from ~50% to ~35%) erodes core profitability and suggests persistent cost, mix or pricing pressure. Such structural compression reduces earnings power and requires sustained remediation (pricing, cost cuts or higher-value product mix) to restore historical margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Sustained re-acceleration of revenue (22.6% in 2026) indicates recovering end-market demand and better commercial traction. Over 2–6 months this supports higher capacity utilization, revenue visibility and the potential to convert scale into steadier operating profits if the trend persists.
Read all positive factors
NGL Fine-Chem Ltd. (NGLFINE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.47B
Dividend Yield0.13%
Average Volume (3M)156.00
Price to Earnings (P/E)26.4
Beta (1Y)0.94
Revenue Growth36.08%
EPS Growth130.40%
CountryIN
Employees682
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)33.49
Shares Outstanding6,178,024
10 Day Avg. Volume192
30 Day Avg. Volume156
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NGL Fine-Chem Ltd. Business Overview & Revenue Model
Company Description
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, ...
How the Company Makes Money
null...
NGL Fine-Chem Ltd. Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.09B | 5.01B | 3.68B | 3.39B | 2.78B | 3.18B |
| Gross Profit | 2.08B | 1.76B | 1.86B | 1.70B | 1.38B | 1.66B |
| EBITDA | 476.13M | 726.90M | 338.69M | 678.69M | 404.87M | 788.78M |
| Net Income | 206.86M | 481.27M | 211.24M | 413.17M | 204.96M | 498.97M |
Balance Sheet | ||||||
| Total Assets | 4.84B | 5.45B | 4.33B | 3.56B | 2.87B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 637.29M | 442.99M | 655.28M | 553.14M | 525.02M | 295.49M |
| Total Debt | 882.03M | 1.09B | 731.53M | 340.04M | 324.99M | 300.01M |
| Total Liabilities | 1.84B | 2.16B | 1.51B | 929.04M | 645.30M | 737.10M |
| Stockholders Equity | 3.00B | 3.29B | 2.82B | 2.63B | 2.23B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | -82.44M | -503.10M | -949.49M | -80.59M | 38.80M | -425.52M |
| Operating Cash Flow | 167.72M | 395.40M | 358.22M | 204.65M | 352.86M | 138.25M |
| Investing Cash Flow | -143.73M | -712.79M | -345.53M | -268.17M | -270.20M | -142.03M |
| Financing Cash Flow | -10.81M | 340.13M | -10.81M | -10.81M | -10.81M | -10.81M |
NGL Fine-Chem Ltd. Technical Analysis
Positive
1427.00
Price Trends
2311.15
Positive
2105.81
Positive
1754.61
Positive
Market Momentum
117.52
Negative
60.93
Neutral
76.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NGLFINE, the sentiment is Positive. The current price of 1427 is below the 20-day moving average (MA) of 2436.08, below the 50-day MA of 2311.15, and below the 200-day MA of 1754.61, indicating a bullish trend. The MACD of 117.52 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 76.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NGLFINE.
NGL Fine-Chem Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹115.31B | 17.02 | ― | 0.44% | 12.51% | 9.82% | |
71 Outperform | ₹380.05B | 27.20 | ― | 1.07% | 14.50% | 47.08% | |
70 Outperform | ₹17.47B | 26.41 | ― | 0.13% | 36.08% | 130.40% | |
65 Neutral | ₹53.25B | 29.36 | ― | ― | ― | ― | |
62 Neutral | ₹9.37B | 20.27 | ― | 1.96% | 8.23% | -33.30% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | ₹35.30B | 26.18 | ― | 0.13% | 13.30% | 39.45% |
* Basic Materials Sector Average
IN:NGLFINE
NGL Fine-Chem Ltd.
2,700.65
1,517.05
128.17%
IN:GLAND
Gland Pharma Ltd.
2,313.30
802.42
53.11%
IN:KOPRAN
Kopran Limited
193.75
13.67
7.59%
IN:MARKSANS
Marksans Pharma Limited
248.90
-0.17
-0.07%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
378.10
109.22
40.62%
IN:SENORES
Senores Pharmaceuticals Ltd.
1,113.75
609.65
120.94%
NGL Fine-Chem Ltd. Corporate Events
NGL Fine-Chem Outlook Raised to Stable by Crisil
Mar 13, 2026
NGL Fine-Chem Limited announced that Crisil Ratings has revised the outlook on its long-term bank loan facilities to Stable from Negative, while reaffirming the long-term rating at Crisil BBB+. The short-term rating has been reaffirmed at Crisil A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.